These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8370389)

  • 1. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
    Houbiers JG; Nijman HW; van der Burg SH; Drijfhout JW; Kenemans P; van de Velde CJ; Brand A; Momburg F; Kast WM; Melief CJ
    Eur J Immunol; 1993 Sep; 23(9):2072-7. PubMed ID: 8370389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides.
    Bertholet S; Iggo R; Corradin G
    Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
    Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
    Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
    Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
    Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules.
    Gnjatic S; Bressac-de Paillerets B; Guillet JG; Choppin J
    Eur J Immunol; 1995 Jun; 25(6):1638-42. PubMed ID: 7542198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
    Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
    Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
    Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA
    Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
    Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
    J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.
    Nijman HW; Houbiers JG; van der Burg SH; Vierboom MP; Kenemans P; Kast WM; Melief CJ
    J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):121-6. PubMed ID: 7506574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas.
    Gnjatic S; Cai Z; Viguier M; Chouaib S; Guillet JG; Choppin J
    J Immunol; 1998 Jan; 160(1):328-33. PubMed ID: 9551988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
    De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
    Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes.
    Nijman HW; Houbiers JG; Vierboom MP; van der Burg SH; Drijfhout JW; D'Amaro J; Kenemans P; Melief CJ; Kast WM
    Eur J Immunol; 1993 Jun; 23(6):1215-9. PubMed ID: 7684681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers.
    Wizel B; Houghten R; Church P; Tine JA; Lanar DE; Gordon DM; Ballou WR; Sette A; Hoffman SL
    J Immunol; 1995 Jul; 155(2):766-75. PubMed ID: 7541824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.